

CTLA4 antibody [BNI3]

Cat. No. GTX75283

Host	Mouse
Clonality	Monoclonal
Isotype	IgG2a
Applications	IHC-P, IHC-Fr, FCM, IP, Activation, EIA, Neutralizing/Inhibition
Reactivity	Human, Baboon, Cynomolgus monkey, Rhesus Monkey

References (10)

Package

100 µg

PRODUCT

Summary

The BNI3 antibody is specific for human CD152, commonly known as CTLA-4, a 33-37 kDa protein expressed as a homodimer on the surface of activated T and B cells, and on thymocytes. CTLA-4 is structurally similar, yet functionally disparate, to the T cell co-stimulatory molecule CD28. Both CTLA-4 and CD28 interact with the co-stimulatory molecules CD80 (B7-1) and CD86 (B7-2) on antigen-presenting cells, with CTLA-4 displaying a higher avidity than CD28. While CD28 typically delivers a potent co-stimulatory signal in support of T cell activation, CTLA-4 appears to act as a negative regulator of T cell activation and may contribute to the suppressor function of Treg cells.

Applications

Application Note

*Optimal dilutions/concentrations should be determined by the researcher.

Suggested dilution	Recommended dilution
IHC-P	Assay dependent
IHC-Fr	Assay dependent
FCM	Assay dependent
IP	Assay dependent
Activation	Assay dependent
EIA	Assay dependent
Neutralizing/Inhibition	Assay dependent

Not tested in other applications.

Properties

Form	Liquid
Buffer	10mM NaH ₂ PO ₄ , 150mM NaCl
Preservative	0.09% Sodium azide
Storage	Store as concentrated solution. Centrifuge briefly prior to opening vial. Store at 4°C.
Concentration	0.5 mg/ml (Please refer to the vial label for the specific concentration.)
Immunogen	Human CTLA-4/human IgG heavy chain fusion protein.



For full product information, images and publications, please visit our [website](#).

Date 2026 / 01 / 28 Page 1 of 2

Purification	Purified by affinity chromatography From tissue culture supernatant
Conjugation	Unconjugated
Note	For laboratory research use only. Not for any clinical, therapeutic, or diagnostic use in humans or animals. Not for animal or human consumption. Purchasers shall not, and agree not to enable third parties to, analyze, copy, reverse engineer or otherwise attempt to determine the structure or sequence of the product.



For full product information, images and publications, please visit our [website](#).

Date 2026 / 01 / 28 Page 2 of 2